Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against ESSA Pharma Inc.

Date: January 27, 2025

Location: New York, NY / ACCESS Newswire

Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against ESSA Pharma Inc. (“ESSA” or “the Company”) (NASDAQ:EPIX) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired ESSA securities between December 12, 2023 and October 31, 2024, both dates inclusive (the “Class Period”).

ESSA Pharma Inc. is a biopharmaceutical company focused on developing novel therapies for the treatment of prostate cancer. The lawsuit alleges that the Company and its officers made false and misleading statements to investors, causing ESSA’s stock price to artificially inflate during the Class Period. As a result, investors who purchased ESSA securities may have suffered financial losses when the alleged misconduct was revealed.

Investors who believe they may be affected by this class action lawsuit are encouraged to contact Bronstein, Gewirtz & Grossman, LLC to discuss their legal rights and options.

How Will This Affect Me?

If you are an investor who purchased or acquired ESSA securities between December 12, 2023 and October 31, 2024, you may be eligible to participate in the class action lawsuit seeking to recover damages for alleged violations of federal securities laws. Contacting a legal representative can help you determine the best course of action to protect your rights and potentially recover any financial losses incurred.

How Will This Affect the World?

The outcome of this class action lawsuit against ESSA Pharma Inc. has the potential to impact not only the Company and its investors, but also the broader biopharmaceutical industry and financial markets. A successful resolution of the allegations could lead to increased transparency and accountability in the industry, while a negative outcome may raise concerns about regulatory compliance and investor protections.

Conclusion

In conclusion, the class action lawsuit filed against ESSA Pharma Inc. highlights the importance of investor vigilance and regulatory oversight in the financial markets. Whether you are directly impacted as an investor or observing the developments from a broader perspective, staying informed and seeking legal guidance can help navigate the complexities of securities litigation and protect your interests.